Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Study sponsor: Apollomics Inc. · APLM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-08-22Actual
Enrollment · participants140Actual
Source updated2025-06-27Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.